- Research works
- 95 ◆ 2% vs 2013–17
- Citations
- 1.7k 17.8 per fractional work
- Top-10% rate
- 18.7% record average 16.5%
- Open access
- 34% world 28%
Not ranked overall: Austrian Breast & Colorectal Cancer Study Group is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 3.5×. Every wedge is a field page.
- Medicine 3.5×
- Biochemistry, Genetics and Molecular Biology 3.5×
- Immunology and Microbiology 3.0×
- Mathematics 2.9×
- Economics, Econometrics and Finance 2.0×
- Decision Sciences 1.9×
- Pharmacology, Toxicology and Pharmaceutics 0.3×
- Neuroscience 0.2×
- Agricultural and Biological Sciences 0.1×
- Computer Science 0.1×
- Chemistry 0.0×
- Social Sciences 0.0×
- Engineering 0.0×
Who are the top researchers at Austrian Breast & Colorectal Cancer Study Group?
Ranked on the composite score, Christian Fesl lead among researchers whose main affiliation is Austrian Breast & Colorectal Cancer Study Group.
- 1 Christian Fesl Austria · #1,479,333 worldwide 14 citations · 16 works
Which keywords describe research at Austrian Breast & Colorectal Cancer Study Group?
By fractional works in all years, weighted toward what it does more of than the world: Chemotherapy, Metastatic Breast Cancer, Breast Cancer, Quality of Life, Clinical Practice Guidelines, Chemotherapy-Induced Peripheral Neuropathy, Taxanes and Radiotherapy.
- Trastuzumab
- Rituximab
- Signaling
- Hepatocellular Carcinoma
- Angiosarcoma
- Hepatitis C Virus
- Genetic Variation
- Palbociclib
- Antiviral Therapy
- Treatment Response
- Gene Expression
- Prognostic Factors
- Dermatological Toxicity
- Treatment
- Molecular Subtypes
- Management
- Radiotherapy
- Chemotherapy-Induced Peripheral Neuropathy
- Quality of Life
- Metastatic Breast Cancer
- Chemotherapy
- Breast Cancer
- Clinical Practice Guidelines
- Taxanes
- Prevention
- Neoadjuvant Therapy
- Survival Analysis
- Epidemiology
- Extravasation
- Prognostic Markers
- Breast Tumours
- Immune Response
- CDK4/6 Inhibitors
- Liver Disease
- Cancer
- Ribavirin
- Epithelioid Hemangioendothelioma
- Insulin Resistance
- Nuclear Receptors
- Transcriptional Regulation
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy14▲ 21×18 topics
- Metastatic Breast Cancer13▲ 210×2 topics
- Breast Cancer12▲ 45×10 topics
- Quality of Life11▲ 8.3×14 topics
- Clinical Practice Guidelines10▲ 18×10 topics
- Chemotherapy-Induced Peripheral Neuropathy9▲ 180×1 topic
- Taxanes9▲ 180×1 topic
- Radiotherapy8▲ 22×7 topics
- Prevention7▲ 20×5 topics
- Management7▲ 9.8×6 topics
- Neoadjuvant Therapy7▲ 34×4 topics
- Molecular Subtypes7▲ 83×3 topics
- Survival Analysis7▲ 26×5 topics
- Treatment6▲ 5.2×10 topics
- Epidemiology6▲ 1.62×21 topics
- Dermatological Toxicity6▲ 564×1 topic
- Extravasation6▲ 564×1 topic
- Prognostic Factors6▲ 14×10 topics
- Prognostic Markers6▲ 66×3 topics
- Gene Expression6▲ 10×6 topics
- Breast Tumours6▲ 121×1 topic
- Treatment Response6▲ 121×1 topic
- Immune Response5▲ 8.4×5 topics
- Antiviral Therapy5▲ 32×3 topics
- CDK4/6 Inhibitors5▲ 306×1 topic
- Palbociclib5▲ 306×1 topic
- Liver Disease4▲ 35×2 topics
- Genetic Variation4▲ 13×4 topics
- Cancer4▲ 2.9×20 topics
- Hepatitis C Virus4▲ 76×1 topic
- Ribavirin4▲ 76×1 topic
- Angiosarcoma4▲ 228×1 topic
- Epithelioid Hemangioendothelioma4▲ 228×1 topic
- Hepatocellular Carcinoma3▲ 16×3 topics
- Insulin Resistance3▲ 6.4×3 topics
- Signaling2▲ 21×3 topics
- Nuclear Receptors2▲ 12×3 topics
- Rituximab2▲ 14×2 topics
- Transcriptional Regulation2▲ 8.8×3 topics
- Trastuzumab2▲ 53×2 topics
Which research topics does Austrian Breast & Colorectal Cancer Study Group publish most on?
By volume in 2022–2025: Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Statistical Methods in Clinical Trials and Hepatitis C virus research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Breast Cancer Treatment Studies Cancer Research 1 works
- 2 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
- 3 Statistical Methods in Clinical Trials Statistics and Probability 0 works
- 4 Hepatitis C virus research Hepatology 0 works
- 5 Cancer Risks and Factors Oncology 0 works
- 6 Economic and Financial Impacts of Cancer Economics and Econometrics 0 works
- 7 Medical Imaging Techniques and Applications Radiology, Nuclear Medicine and Imaging 0 works
- 8 Breast Lesions and Carcinomas Pathology and Forensic Medicine 0 works
- 9 HER2/EGFR in Cancer Research Oncology 0 works
- 10 Empathy and Medical Education Psychiatry and Mental health 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Austrian Breast & Colorectal Cancer Study Group's research output changed?
Output in 2018–2022 was 2% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Vienna
- University of Vienna
- TU Wien
- Medical University of Vienna
- BOKU University
- Vienna University of Economics and Business
- Austrian Academy of Sciences
- University of Veterinary Medicine Vienna
- Austrian Institute of Technology
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.